Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaolin Fan

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
The New England Journal of Medicine|May 30, 2020
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate CancerNeal D Shore, Fred Saad, Michael S Cookson, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2024
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral PaltusotineMônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
The New England Journal of Medicine|May 30, 2020
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate CancerNeal D Shore, Fred Saad, Michael S Cookson, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2024
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral PaltusotineMônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, et al.
Pageof 11